Results 61 to 70 of about 179,831 (305)

Tumor site-directed A1R expression enhances CAR T cell function and improves efficacy against solid tumors

Nature Communications
The efficacy of Chimeric Antigen Receptor T cells against solid tumors is limited by immunosuppressive factors in the tumor microenvironment including adenosine, which suppresses Chimeric Antigen Receptor T cells through activation of the A2A receptor ...
Kevin Sek, Amanda X. Y. Chen, Thomas Cole, Jesse D. Armitage, Junming Tong, Kah Min Yap, Isabelle Munoz, Phoebe A. Dunbar, Shiyi Wu, Marit J. van Elsas, Olivia Hidajat, Christina Scheffler, Lauren Giuffrida, Melissa A. Henderson, Deborah Meyran, Fernando Souza-Fonseca-Guimaraes, Dat Nguyen, Yu-Kuan Huang, Maria N. de Menezes, Emily B. Derrick, Cheok Weng Chan, Kirsten L. Todd, Jack D. Chan, Jasmine Li, Junyun Lai, Emma V. Petley, Sherly Mardiana, Anthony Bosco, Jason Waithman, Ian A. Parish, Christina Mølck, Gregory D. Stewart, Lev Kats, Imran G. House, Phillip K. Darcy, Paul A. Beavis   +35 more
doaj   +1 more source

Antigen-induced chimeric antigen receptor multimerization amplifies on-tumor cytotoxicity

Signal Transduction and Targeted Therapy, 2023
Ligand-induced receptor dimerization or oligomerization is a widespread mechanism for ensuring communication specificity, safeguarding receptor activation, and facilitating amplification of signal transduction across the cellular membrane.
Yan Sun, Xiu-Na Yang, Shuang-Shuang Yang, Yi-Zhu Lyu, Bing Zhang, Kai-Wen Liu, Na Li, Jia-Chen Cui, Guang-Xiang Huang, Cheng-Lin Liu, Jie Xu, Jian-Qing Mi, Zhu Chen, Xiao-Hu Fan, Sai-Juan Chen, Shuo Chen   +15 more
doaj   +1 more source

Research Progress of Multi-target CAR-T Cell Therapy for Cancer

Zhongliu Fangzhi Yanjiu, 2022
Chimeric antigen receptor T cell (CAR-T) is a kind of adoptive cell immunotherapy, in which T cells are genetically modified to exert targeted killing effect on tumors.
JIANG Yao, WEN Weihong, YANG Fa, NIE Disen, ZHANG Wuhe, QIN Weijun   +5 more
doaj   +1 more source

Development of novel adenoviral vectors to overcome challenges observed with HAdV-5 based constructs [PDF]

, 2011
Recombinant vectors based on human adenovirus serotype 5 (HAdV-5) have been extensively studied in pre-clinical models and clinical trials over the last two decades.
Julio Alonso-Padilla, Tibor Papp, Győző L Kaján, Mária Benkő, Menzo Havenga, Angelique Lemckert, Balázs Harrach, Andrew H Baker, Harrach, Benkő, Liu, Reddy, Benevento, Reddy, Rux, Bergelson, Wickham, Wolfrum, Arnberg, Burckhardt, Vectors used in gene therapy clinical trials., Appaiahgari, Pearson, Wilson, Chorny, Van Kampen, George, Ranki, Hendrickx, Ilan, Schaack, Aldhamen, Machitani, Appledorn, Perreau, Minamitani, Khare, Lyons, Carlisle, Seiradake, Xu, Khare, Qiu, Waddington, Kalyuzhniy, Vigant, Alba, Jonsson, Lenman, Doronin, Xu, Eichholz, Ganesan, Alemany, Piccolo, Mocanu, Piccolo, Khare, Xu, Lasaro, Zak, Zhang, Barouch, Bradley, Roberts, Gall, Fausther-Bovendo, Sumida, Miyazawa, Teigler, Smith, Molinier-Frenkel, Heemskerk, Hutnick, Tang, Olive, Leen, Joshi, Osada, Perreau, Seregin, Seregin, Fontanellas, Cerullo, Brunetti-Pierri, Seregin, Farrow, McConnell, Belousova, Seregin, Capasso, Green, Doronin, Kreppel, Matsui, Suzuki-Kouyama, Prill, Krasnykh, Zabner, Havenga, Lecollinet, Coughlan, Granio, Parker, Guse, Smith, Nicol, Bruder, Bruder, Baden, Coughlan, Mück-Häusl, Bi, Abbink, Abbink, Mastrangeli, Abrahamsen, Brough, Stone, Sirena, Stone, Seshidhar Reddy, Hemminki, Creech, Vogels, Kuhn, Di, Havenga, Kahl, Vogels, Lemckert, Teigler, Tameris, Ouédraogo, Keefer, Baden, Gilbert, Baden, Zahn, Johnson, Dakin, Alexander, Alexander, Gurwith, Lemiale, Jarecki-Khan, Saderi, Ko, Bangari, Ayalew, Hammond, Tuboly, Fischer, Hu, Greenall, Brake, Lopez-Gordo, Kremer, Soudais, Soudais, Silva, Puig, Fernandes, Tandon, Bangari, Nguyen, Lenaerts, Ying, van Olphen, Zakhartchouk, Cauthen, Reddy, Reddy, Li, Lenaerts, Sharma, Sharma, Roy, Cohen, Xiang, Quinn, Farina, Roy, Colloca, Barnes, O'Hara, Antrobus, Stanley, Tan, Michou, Ojkic, Sheppard, Corredor, Cherenova, Shashkova, Logunov, Both, Xu, Khatri, Hofmann, Löser, Both, Martiniello-Wilks, Tang, Fraser, Bridgeman, Doszpoly, Cortés-Hinojosa, Wigand, Kajon, Guy, Benkö, Lu, Günes, Wellehan, Phan   +215 more
core   +4 more sources

Applying an Ethical Lens to the Treatment of People With Multiple Sclerosis

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT The practice of neurology requires an understanding of clinical ethics for decision‐making. In multiple sclerosis (MS) care, there are a wide range of ethical considerations that may arise. These involve shared decision‐making around selection of a disease‐modifying therapy (DMT), risks and benefits of well‐studied medications in comparison to
Methma Udawatta, Farrah J. Mateen
wiley   +1 more source

Antibody-conjugated lipid nanoparticles for in vivo CAR-T cell engineering: From concept to clinical translation

Nano Biomedicine and Engineering
Chimeric antigen receptor T cell therapy represents a transformative advancement in immunotherapy, wherein engineered T cells target tumor antigens, achieving high response rates in hematological malignancies.
Zhitong Guo, Mengjie Zhang, Yuanyu Huang
doaj   +1 more source

CD171- and GD2-specific CAR-T cells potently target retinoblastoma cells in preclinical in vitro testing [PDF]

, 2019
BACKGROUND: Chimeric antigen receptor (CAR)-based T cell therapy is in early clinical trials to target the neuroectodermal tumor, neuroblastoma. No preclinical or clinical efficacy data are available for retinoblastoma to date.
Andersch, Lena, Eggert, Angelika, Flemmig, Carina, Grunewald, Laura, Henssen, Anton, Jensen, Michael C., Joussen, Antonia, Klaus, Anika, Künkele, Annette, Radke, Josefine, Rossig, Claudia, Schulte, Johannes H., Schumann, Elisa, Schwiebert, Silke, Winkler, Annika, Zirngibl, Felix   +15 more
core   +2 more sources

Rheumatologic Manifestations of Patients With Type B Insulin Resistance

Arthritis Care &Research, EarlyView.
Objective The objectives of this study were to identify laboratory and clinical features associated with type B insulin resistance (TBIR), a rare condition caused by autoantibodies that inhibit the insulin receptor, most frequently occurring in the setting of systemic lupus erythematosus (SLE), and to increase awareness of this rare, life‐threatening ...
S. Amara Ogbonnaya, Sandra G. Williams, Raphael A. Kirou, Marissa Lightbourne, Rebecca J. Brown   +4 more
wiley   +1 more source

T cell receptor-engineered T cells for leukemia immunotherapy

Cancer Cell International, 2019
At present, refractory and relapse are major issues for leukemia therapy and a major cause of allogeneic hematopoietic stem cell transplant failure. Over the last decade, many studies have demonstrated that adoptive cancer antigen-specific T cell therapy
Yikai Zhang, Yangqiu Li
doaj   +1 more source

New directions in cellular therapy of cancer: a summary of the summit on cellular therapy for cancer [PDF]

, 2012
A summit on cellular therapy for cancer discussed and presented advances related to the use of adoptive cellular therapy for melanoma and other cancers. The summit revealed that this field is advancing rapidly.
A Lundqvist, A Somers, C Berger, CA Tran, Carolina Berger, Cornelis JM Melief, Daniel J Powell, David F Stroncek, DG Song, DJ Powell Jr, DL Porter, Francesco M Marincola, G Mostoslavsky, GG Kenter, Gustavo Mostoslavsky, J Jin, J Staerk, James R Heath, Jeffrey S Miller, JN Kochenderfer, JN Kochenderfer, John O'Shea, JS Miller, K Takahashi, L Gattinoni, L Gattinoni, L Gattinoni, L Gattinoni, LA Johnson, Luca Gattinoni, M Kalos, M Kalos, M Kalos, Mahendra Rao, Mark E Dudley, Martin A Cheever, ME Dudley, ME Dudley, Michael Kalos, Nicholas P Restifo, P Muranski, Peter Flynn, PF Robbins, RA Morgan, Richard W Childs, SA Rosenberg, Steven A Rosenberg, TS Park, X Wang   +48 more
core   +4 more sources